ANALYSIS: Abbott/St Jude Merger Would Make Sense But Vascular Closure Potential Snag
This article was originally published in Clinica
Media reports of a potential $25bn bid by Abbott Laboratories for St Jude Medical, Inc., may have been promptly knocked down by Abbott, but that has not stopped shares of the cardiology firm rallying in the wake of the rumors.
You may also be interested in...
Abbott and St. Jude Medical are to lighten their cardiovascular portfolios – and hopefully facilitate the completion of Abbott's pending $25bn acquisition of St. Jude – by selling three product lines to Terumo. Two of the three product lines to be divested come as little surprise, but one product was acquired by Abbott only earlier this year.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.